Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 293-299

  Iwamoto, M ^a   Wenning, L A ^a   Petry, A S ^a   Laethem, M ^a   De Smet, M ^a   Kost, J T ^a   Merschman, S A ^a   Strohmaier, K M ^a   Ramael, S ^b   Lasseter, K C ^c   Stone, J A ^a   Gottesdiener, K M ^a   Wagner, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SGS Medisearch International NV   (Belgium)

^c PharmaNet Development Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; ORGANIC CHEMICALS; REFERENCE VALUES;

EID: 38349194563     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100281     Document Type: Article

References (16)

1. 2006 Report on the global AIDS epidemic, UNAIDS, May 2006. Available at 〈http://www.unaids.org/en/Publications/default.asp〉. Accessed 2 March 2007.
2. Esposito, D. & Craigie, R. HIV integrase structure and function. Adv. Virus Res. 52, 319-333 (1999).
3. Asante-Appiah, E. & Skalka, A.M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52, 351-369 (1999).
4. Miller, M.D. et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract THAA0302]. In XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada (International AIDS Society, Geneva, Switzerland, 2006).
5. Summa, V. et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials [abstract THPE0020]. In XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada (International AIDS Society, Geneva, Switzerland, 2006).
6. Markowitz, M. et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune. Defic. Syndr. 43, 509-515 (2006).
7. Markowitz, M. et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment naive HIV-1 infected patients [abstract THLB0214]. In XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada (International AIDS Society, Geneva, Switzerland, 2006).
8. Grinsztejn, B. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 369, 1261-1269 (2007).
9. Cooper, D. et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105a LB]. Presented at 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA. Available at 〈http://www.retroconference.org/2007/abstracts/30687.htm〉.
10. Steigbigel, R. et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105b LB]. Presented at 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA. Available at 〈http://www.retroconference.org/2007/abstracts/30688.htm〉.
11. Kassahun, K. et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers [abstract A-372]. In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2006, San Francisco, CA (ASM Press, Herndon, VA, 2006).
12. Kappelhoff, B.S. et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43, 845-853 (2004).
13. Aarnoutse, R.E., Schapiro, J.M., Boucher, C.A.B., Hekster, Y.A. & Burger, D.M. Therapeutic drug monitoring. Drugs 63, 741-753 (2003).
14. Acosta, E.P. et al. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retroviruses 18, 825-834 (2002).
15. Moyle, G.J. & Back, D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2, 105-113 (2001).
16. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 10, 2006. 〈http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf〉.